Seattle Children's Hospital

Seattle Children’s Hospital is home to the largest pediatric brain tumor program in the Northwestern United States. With an international reputation for comprehensive care of pediatric brain tumors, Seattle Children’s Brain Tumor Program treats central nervous system (CNS) tumors in children, adolescents and young adults. For more than a decade, their Cancer and Blood Disorders Center has consistently ranked among the top pediatric oncology programs in the country by U.S. News & World Report. Seattle Children’s has ranked as one of the nation’s best children’s hospitals for more than 25 years.

At Seattle Children’s, children receive the most advanced care, including access to advanced neurosurgery, proton radiation therapy and clinical trials offering promising new treatments.

Young patients have the opportunity to take part in research as part of their medical treatment. Seattle Children’s doctors and researchers are leaders in developing studies of new drugs and other new treatments, including Dr. Sarah Leary, who is the director of their Brain Tumor Program, the vice-chair of the Children’s Oncology Group (COG) CNS committee, and the principal investigator of research on tumor paint.

Seattle Children’s is also an international leader in immunotherapy. Dr. Nicholas Vitanza's phase 1 chimeric antigen receptor (CAR) T cell trials, called BrainChild-01, -02, and -03, use a patient’s engineered T cells to target CNS tumors in children and young adults with recurrent/refractory central nervous system tumors or with diffuse intrinsic pontine glioma (DIPG) or diffuse midline glioma, H3 K27M-mutant (DMG).

Contact

Jeffrey Stevens | Clinical Research Coordinator